Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
Sponsor: Oman Ministry of Health
Summary
This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis. Methods: A prospective, open label, single-arm interventional clinical trial, will conduct at Nizwa Hospital from March 1st, 2026, to August 31th , 2026, and includes thirty (30) end-stage kidney disease diabetic and non-diabetic patients on chronic peritoneal dialysis, will receive selective SGLT2i Dapagliflozin 10 mg once daily (OD). Clinical and laboratory parameters will be assessed at baseline, then three and six months after drug initiation. The primary outcomes are:1- change in ultrafiltration volume, 2- change in Kt/V (dialysis adequacy), 3. Change in the mean 24-hour urine volume.
Official title: Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients: A Six-month Prospective .Study
Key Details
Gender
All
Age Range
13 Years - Any
Study Type
INTERVENTIONAL
Enrollment
38
Start Date
2026-04-01
Completion Date
2027-01-31
Last Updated
2026-03-24
Healthy Volunteers
No
Conditions
Interventions
Dapagliflozin
study the effect of selective SGLT2i Dapagliflozin on peritoneal dialysis patients regarding UF/Kt/v and residual renal function
Locations (1)
Jehad Badawi AL LAHAM
Nizwá, Oman